These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38216431)

  • 41. The zebrafish for preclinical psilocybin research.
    Syed OA; Tsang B; Gerlai R
    Neurosci Biobehav Rev; 2023 Oct; 153():105381. PubMed ID: 37689090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
    Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
    Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beating pain with psychedelics: Matter over mind?
    Elman I; Pustilnik A; Borsook D
    Neurosci Biobehav Rev; 2022 Mar; 134():104482. PubMed ID: 34922987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is psilocybin an effective antidepressant and what is its Mechanism of action?
    Mann JJ
    Cell Rep Med; 2023 Jan; 4(1):100906. PubMed ID: 36652915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The psychedelic effects of cannabis: A review of the literature.
    Wolinsky D; Barrett FS; Vandrey R
    J Psychopharmacol; 2024 Jan; 38(1):49-55. PubMed ID: 37947321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects.
    Hosanagar A; Cusimano J; Radhakrishnan R
    J Clin Psychiatry; 2021 Feb; 82(2):. PubMed ID: 33988926
    [No Abstract]   [Full Text] [Related]  

  • 50. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
    Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
    Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
    Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
    Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beyond the 5-HT
    Cameron LP; Benetatos J; Lewis V; Bonniwell EM; Jaster AM; Moliner R; Castrén E; McCorvy JD; Palner M; Aguilar-Valles A
    J Neurosci; 2023 Nov; 43(45):7472-7482. PubMed ID: 37940583
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DARK Classics in Chemical Neuroscience: Psilocybin.
    Geiger HA; Wurst MG; Daniels RN
    ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psilocybin for Trauma-Related Disorders.
    Khan AJ; Bradley E; O'Donovan A; Woolley J
    Curr Top Behav Neurosci; 2022; 56():319-332. PubMed ID: 35711024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serotonin 5-HT
    Erkizia-Santamaría I; Alles-Pascual R; Horrillo I; Meana JJ; Ortega JE
    Biomed Pharmacother; 2022 Oct; 154():113612. PubMed ID: 36049313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psilocybin: The most effective moral bio-enhancer?
    Rakić V
    Bioethics; 2023 Sep; 37(7):683-689. PubMed ID: 37376901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.
    Rosenblat JD; Leon-Carlyle M; Ali S; Husain MI; McIntyre RS
    Am J Psychiatry; 2023 May; 180(5):395-396. PubMed ID: 36945824
    [No Abstract]   [Full Text] [Related]  

  • 60. Return of the psychedelics: Psilocybin for treatment resistant depression.
    Patra S
    Asian J Psychiatr; 2016 Dec; 24():51-52. PubMed ID: 27931907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.